目的:探讨益气除痰方对BALB/c裸小鼠肺癌A549移植瘤的抑制作用及其机制。方法:人肺腺癌细胞A549接种BALB/c裸鼠40只,随机分为模型组(生理盐水)、顺铂注射液(0.002 g/kg)组、益气除痰方低剂量(3.0g/kg)组、益气除痰方高剂量(6.0 g/kg)组...目的:探讨益气除痰方对BALB/c裸小鼠肺癌A549移植瘤的抑制作用及其机制。方法:人肺腺癌细胞A549接种BALB/c裸鼠40只,随机分为模型组(生理盐水)、顺铂注射液(0.002 g/kg)组、益气除痰方低剂量(3.0g/kg)组、益气除痰方高剂量(6.0 g/kg)组、联合用药(益气除痰方6.0 g/kg+顺铂注射液组0.002 g/kg)组。造模第8天,中药灌胃,1次/d,每次0.2 m L,连续14 d。第17天,顺铂注射液腹腔注射,1次/d,每次0.2 m L,连续5 d。第22天,麻醉处死裸鼠,检测瘤体积和瘤质量,计算抑瘤率。采用免疫组织化学法、Western blot法及RTQ-PCR法检测肿瘤组织中钙联蛋白(calnexin,CNX)及调控转录因子X盒结合蛋白1(X-box binding protein 1,XBP1)的表达。结果:顺铂注射液组、益气除痰方高剂量组及联合用药组瘤质量及瘤体积较模型组显著降低(P<0.05或P<0.01),且联合用药组显著优于顺铂注射液组(P<0.01)。免疫组织化学法、Western blot法及RTQ-PCR法结果均显示顺铂注射液组、益气除痰方高剂量及联合用药组CNX及XBP1的表达较模型组显著降低(P<0.01),且联合用药组优于顺铂注射液组(P<0.05或P<0.01)。结论:益气除痰方能抑制A549肺癌生长,与顺铂联用能起到增效作用,其机制可能与下调相关分子伴侣蛋白CNX及XBP1的表达而抑制未折叠蛋白反应(unfolded protein response,UPR),从而导致肿瘤细胞凋亡有关。展开更多
Objectives： To investigate the role of prolyl 4-hydroxylase beta polypeptide （P4HB） expressed in lung carcinoma and the intervention effect of Yiqi Chutan Formula （益气除痰方, YQCTF）. Methods： Lung carcinoma mod...Objectives： To investigate the role of prolyl 4-hydroxylase beta polypeptide （P4HB） expressed in lung carcinoma and the intervention effect of Yiqi Chutan Formula （益气除痰方, YQCTF）. Methods： Lung carcinoma model was established by subcutaneously inoculating LEWIS lung carcinoma cells in C57BL/6J mice. The differential expression of P4HB protein between the YQCTF （3.0 g/kg, gavage, once daily, 21 days） group and the control group was acquired by a 2 fluorescence difference gel electrophoresis （2D-DIGE）, verified by Westem blotting and identified by matrix-assisted laser desorption ionization time of flight mass spectrometry （MALDI-TOF/＇IOF-MS）. The expression of P4HB and P4HB mRNA in cultured A549 cells from cisplatin （DDP） 1.5μg/mL group and 15% serum combined with DDP 1.5 μg/mL group were detected by cellular immunohistochemistry and reverse chain reaction, respectively. Results： The proteomics research discovered that one-third of differential proteins including P4HB were decreased in the YQCTF group （P〈0.01）. Clinical pathology and tissue microarray studies showed that P4HB expression in lung cancer tissue was stronger than adjacent tissues and normal lung epithelial （P〈0.01）. In the YQCTF and DDP combined groups, the expression of P4HB and P4HB mRNA in A549 cell were decreased significantly （P〈0.01）. Conclusion： YQCTF could inhibit the LEWIS lung carcinoma＇s growth, decrease the expression of P4HB in LEWIS lung carcinoma and A549 cells. YQCTF might take effect through regulating P4HB in endoplasmic reticulum to inhibit the incidence and growth process of lung cercinoma.展开更多
文摘目的:探讨益气除痰方对BALB/c裸小鼠肺癌A549移植瘤的抑制作用及其机制。方法:人肺腺癌细胞A549接种BALB/c裸鼠40只,随机分为模型组(生理盐水)、顺铂注射液(0.002 g/kg)组、益气除痰方低剂量(3.0g/kg)组、益气除痰方高剂量(6.0 g/kg)组、联合用药(益气除痰方6.0 g/kg+顺铂注射液组0.002 g/kg)组。造模第8天,中药灌胃,1次/d,每次0.2 m L,连续14 d。第17天,顺铂注射液腹腔注射,1次/d,每次0.2 m L,连续5 d。第22天,麻醉处死裸鼠,检测瘤体积和瘤质量,计算抑瘤率。采用免疫组织化学法、Western blot法及RTQ-PCR法检测肿瘤组织中钙联蛋白(calnexin,CNX)及调控转录因子X盒结合蛋白1(X-box binding protein 1,XBP1)的表达。结果:顺铂注射液组、益气除痰方高剂量组及联合用药组瘤质量及瘤体积较模型组显著降低(P<0.05或P<0.01),且联合用药组显著优于顺铂注射液组(P<0.01)。免疫组织化学法、Western blot法及RTQ-PCR法结果均显示顺铂注射液组、益气除痰方高剂量及联合用药组CNX及XBP1的表达较模型组显著降低(P<0.01),且联合用药组优于顺铂注射液组(P<0.05或P<0.01)。结论:益气除痰方能抑制A549肺癌生长,与顺铂联用能起到增效作用,其机制可能与下调相关分子伴侣蛋白CNX及XBP1的表达而抑制未折叠蛋白反应(unfolded protein response,UPR),从而导致肿瘤细胞凋亡有关。
基金Supported by the National Natural Science Fundation of China(No.30772862)Guangdong Natural Science Fund(No.2010-3)Project of Guangdong University Talent Fund(No.2010-79)
文摘Objectives： To investigate the role of prolyl 4-hydroxylase beta polypeptide （P4HB） expressed in lung carcinoma and the intervention effect of Yiqi Chutan Formula （益气除痰方, YQCTF）. Methods： Lung carcinoma model was established by subcutaneously inoculating LEWIS lung carcinoma cells in C57BL/6J mice. The differential expression of P4HB protein between the YQCTF （3.0 g/kg, gavage, once daily, 21 days） group and the control group was acquired by a 2 fluorescence difference gel electrophoresis （2D-DIGE）, verified by Westem blotting and identified by matrix-assisted laser desorption ionization time of flight mass spectrometry （MALDI-TOF/＇IOF-MS）. The expression of P4HB and P4HB mRNA in cultured A549 cells from cisplatin （DDP） 1.5μg/mL group and 15% serum combined with DDP 1.5 μg/mL group were detected by cellular immunohistochemistry and reverse chain reaction, respectively. Results： The proteomics research discovered that one-third of differential proteins including P4HB were decreased in the YQCTF group （P〈0.01）. Clinical pathology and tissue microarray studies showed that P4HB expression in lung cancer tissue was stronger than adjacent tissues and normal lung epithelial （P〈0.01）. In the YQCTF and DDP combined groups, the expression of P4HB and P4HB mRNA in A549 cell were decreased significantly （P〈0.01）. Conclusion： YQCTF could inhibit the LEWIS lung carcinoma＇s growth, decrease the expression of P4HB in LEWIS lung carcinoma and A549 cells. YQCTF might take effect through regulating P4HB in endoplasmic reticulum to inhibit the incidence and growth process of lung cercinoma.
